CNR1 and Alzheimer disease: Although CBD treatment has not been identified for modulation of Ramp3 and the semaphorin genes in the past per AD pathology, stimulation of some cannabinoid receptors (e.g., CB1R) is known to increase Ramp3 expression (Glenn et al., 2024).